.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean consequence of 11 months, people along with metastatic stomach cysts who acquired biomarker-matched therapies based on distributing lump DNA profiling showed a more significant scientific perk than those obtaining incomparable treatment.